UAE – Bravo Pharma and G42 Healthcare, an artificial intelligence (AI)-powered healthcare company, have joined forces for the future of genomics in the United Arab Emirates.
Bravo Pharma and G42 Healthcare have joined forces to create AI-based health services across the UAE region and beyond.
The partnership agreement aligns with G42 Healthcare’s vision for a more personalized, intelligent, and value-based healthcare model.
The genomic collaboration comes after the Abu Dhabi-based company established Biogenix Labs, UAE’s first COVID-19-accredited large-scale throughput laboratory.
G42 Healthcare also launched IROS, the region’s first contract research organization for clinical research.
Additionally, the AI-powered company set up the Omics Centre of Excellence, the UAE region’s largest and most technologically advanced Omics facility.
G42 Healthcare aims to transform the traditional healthcare ecosystem across the UAE region and beyond, by harnessing AI and advanced medical technologies.
Leveraging their combined expertise, the two parties will co-develop highly efficient clinical reporting systems using bioinformatics and AI.
On his part, the Chief Medical Director (CMD) of Bravo Pharma, Rakesh Pandey, said: “As time and technology advance, we have the duty to provide everyone with the best and leading healthcare possible to ensure the highest quality of life for all.”
The partnership will build on the research activities of Bravo Pharma CMD Rakesh Pandey, who has been the center of the company’s operations on extending the field of genomics and pre-diagnosis of solid cancer.
“With G42 Healthcare’s AI development and our core new drug discovery cytogenetic, targeted therapy, and advanced diagnostics competencies, we will be able to spearhead the region’s genome and health data computation processes,” stated Rakesh Pandey.
The collaboration will enable G42 Healthcare to deploy its best-in-class sequencing technologies to provide clinical genomics sequencing services coupled with clinical reporting and bioinformatics.
Prior to this strategic alliance, Bravo Pharma and G42 Healthcare jointly organized a health conference focused on clinical genomics, proteomics, and somalogic at the Republicans Oncology Centre in Tashkent, Uzbekistan
The one-of-its-kind conference was attended by doctors from various oncology regional hospitals and specialists from G42 Healthcare Abu Dhabi, Dr. Azza Attia, and Mohd Rafiq M Zuraiqi.
Moreover, global healthcare company Bravo Pharma Group and the Uzbekistan-based Republicans Oncology Centre have set up the first Reference Oncology Diagnostic center in Tashkent.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
